Live-attenuated vaccination for measles, mumps, and rubella in pediatric liver transplantation

被引:2
|
作者
Keutler, Anne [1 ]
Lainka, Elke [2 ]
Posovszky, Carsten [1 ,3 ]
机构
[1] Univ Med Ctr Ulm, Dept Pediat & Adolescent Med, Ulm, Germany
[2] Univ Duisburg Essen, Univ Childrens Hosp Essen, Essen, Germany
[3] Univ Childrens Hosp Zurich, Gastroenterol & Nutr, Steinwiesstr 75, CH-8032 Zurich, Switzerland
关键词
children; immunization; liver transplantation; measles; mumps; vaccination; ZOSTER-VIRUS VACCINATION; IMMUNOSUPPRESSED CHILDREN; ORGAN-TRANSPLANTATION; SAFE IMMUNIZATIONS; DISEASES; VACCINES; RECIPIENTS; THERAPY;
D O I
10.1111/petr.14687
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
BackgroundInfections are a serious short- and long-term problem after pediatric organ transplantation. In immunocompromised patients, they can lead to transplant rejection or a severe course with a sometimes fatal outcome. Vaccination is an appropriate means of reducing morbidity and mortality caused by vaccine-preventable diseases. Unfortunately, due to the disease or its course, it is not always possible to establish adequate vaccine protection against live-attenuated viral vaccines (LAVVs) prior to transplantation. LAVVs such as measles, mumps, and rubella (MMR) are still contraindicated in solid organ transplant recipients receiving immunosuppressive therapy (IST), thus creating a dilemma.AimThis review discusses whether, when, and how live-attenuated MMR vaccines can be administered effectively and safely to pediatric liver transplant recipients based on the available data.Material and MethodsWe searched PubMed for literature on live-attenuated MMR vaccination in pediatric liver transplantation (LT).ResultsNine prospective observational studies and three retrospective case series were identified in which at least 833 doses of measles vaccine were administered to 716 liver transplant children receiving IST. In these selected patients, MMR vaccination was well tolerated and no serious adverse reactions to the vaccine were observed. In addition, an immune response to the vaccine was demonstrated in patients receiving IST.ConclusionDue to inadequate vaccine protection in this high-risk group, maximum efforts must be made to ensure full immunization. MMR vaccination could also be considered for unprotected patients after LT receiving IST following an individual risk assessment, as severe harm from live vaccines after liver transplantation has been reported only very rarely. To this end, it is important to establish standardized and simple criteria for the selection of suitable patients and the administration of the MMR vaccine to ensure safe use.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Multimodal safety assessment of measles-mumps-rubella vaccination after pediatric liver transplantation
    Pittet, Laure F.
    Verolet, Charlotte M.
    McLin, Valerie A.
    Wildhaber, Barbara E.
    Rodriguez, Maria
    Cherpillod, Pascal
    Kaiser, Laurent
    Siegrist, Claire-Anne
    Posfay-Barbe, Klara M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 (03) : 844 - 854
  • [2] Detection of Live Attenuated Measles Virus in the Respiratory Tract Following Subcutaneous Measles-Mumps-Rubella Vaccination
    Watkins, Timothy A.
    Brockhurst, Jacqueline K.
    Germain, Gregory
    Griffin, Diane E.
    Foxman, Ellen F.
    JOURNAL OF INFECTIOUS DISEASES, 2024,
  • [3] EFFICACY AND SAFETY OF VACCINATION OF MARROW TRANSPLANT RECIPIENTS WITH A LIVE ATTENUATED MEASLES, MUMPS, AND RUBELLA VACCINE
    LJUNGMAN, P
    FRIDELL, E
    LONNQVIST, B
    BOLME, P
    BOTTIGER, M
    GAHRTON, G
    LINDE, A
    RINGDEN, O
    WAHREN, B
    JOURNAL OF INFECTIOUS DISEASES, 1989, 159 (04): : 610 - 615
  • [4] Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation
    Alisha Pandit
    Houry Leblebjian
    Sarah P. Hammond
    Jacob P. Laubach
    Paul G. Richardson
    Lindsey R. Baden
    Francisco M. Marty
    Nicolas C. Issa
    Bone Marrow Transplantation, 2018, 53 : 942 - 945
  • [5] Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation
    Pandit, Alisha
    Leblebjian, Houry
    Hammond, Sarah P.
    Laubach, Jacob P.
    Richardson, Paul G.
    Baden, Lindsey R.
    Marty, Francisco M.
    Issa, Nicolas C.
    BONE MARROW TRANSPLANTATION, 2018, 53 (07) : 942 - 945
  • [6] Safety of Live-Attenuated Measles, Mumps, and Rubella Vaccine Administered Within 2 Years of Hematopoietic Cell Transplant
    Desjardins, Michael
    Mitre, Xhoi
    Sherman, Amy C.
    Walsh, Stephen R.
    Cheng, Matthew P.
    Kanjilal, Sanjat
    Ho, Vincent T.
    Baden, Lindsey R.
    Issa, Nicolas C.
    OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (12):
  • [7] MEASLES, MUMPS, AND RUBELLA VACCINATION
    MILLER, E
    NOKES, DJ
    ANDERSON, RM
    BMJ-BRITISH MEDICAL JOURNAL, 1992, 304 (6839): : 1440 - 1441
  • [8] MEASLES, MUMPS, AND RUBELLA VACCINATION
    HILL, A
    BRITISH MEDICAL JOURNAL, 1992, 304 (6829): : 779 - 779
  • [9] VACCINATION OF MARROW TRANSPLANT PATIENTS WITH ATTENUATED MEASLES, MUMPS AND RUBELLA VACCINE
    LJUNGMAN, P
    FRIDELL, E
    BOLME, P
    GAHRTON, G
    LINDE, A
    LONNQVIST, B
    RINGDEN, O
    WAHREN, B
    BONE MARROW TRANSPLANTATION, 1988, 3 : 265 - 265
  • [10] Live-attenuated measles, mumps, and rubella booster vaccine in children diagnosed with rheumatic disease: A single-center study
    Cakmak, Figen
    Akgun, Ozlem
    Demirkan, Fatma Gul
    Tanatar, Ayse
    Kayaalp, Gulsah Kavrul
    Keskindemirci, Gonca
    Guliyeva, Vafa
    Omeroglu, Rukiye Eker
    Gokcay, Emine Gulbin
    Ayaz, Nuray Aktay
    EUROPEAN JOURNAL OF PEDIATRICS, 2023, 182 (01) : 135 - 140